- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01322347
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening: 2-3 weeks prior to enrollment in Stage 1.
Stage 1 (Run-In): 1-4weeks depending on qualification for Stage 2.
Stage 2 (Randomized Blinded Treatment): 12 months unless withdrawn prematurely.
Stage 3 (Open-Label Treatment): The duration of Stage 2 plus Stage 3 is intended to be 18 months regardless of treatment assignment in Stage 2.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Investogator
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Investigator
-
-
-
-
Arkansas
-
Paragould, Arkansas, United States, 72450
- Investigator
-
Pine Bluff, Arkansas, United States, 71603
- Investigator
-
-
California
-
Alhambra, California, United States, 91801
- Investigator
-
Beverly Hills, California, United States, 90211
- Investigator
-
Glendale, California, United States, 91204
- Investigator
-
La Mesa, California, United States, 91942
- Investigator
-
Long Beach, California, United States, 90807
- Investigator
-
Lynwood, California, United States, 90262
- Investigator
-
Paramount, California, United States, 90723
- Investigator
-
Whittier, California, United States, 90603
- Investigator
-
-
Florida
-
Pembroke Pines, Florida, United States, 33025
- Investigator
-
-
Georgia
-
Augusta, Georgia, United States, 30901
- Investigator
-
Macon, Georgia, United States, 31217
- Investigator
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Investigator
-
-
Illinois
-
Hines, Illinois, United States, 60141
- Investigator
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Investigator
-
-
Michigan
-
Detroit, Michigan, United States, 48236
- Investigator
-
Pontiac, Michigan, United States, 48341
- Investigator
-
Southfield, Michigan, United States, 48034
- Investigator
-
-
New Jersey
-
Eatontown, New Jersey, United States, 07724
- Investigator
-
-
New York
-
Brooklyn, New York, United States, 11212
- Investigator
-
Fresh Meadows, New York, United States, 11365
- Investigator
-
Great Neck, New York, United States, 11021
- Investigator
-
Orchard Park, New York, United States, 14127
- Investigator
-
The Bronx, New York, United States, 10461
- Investigator
-
-
Oklahoma
-
Bethany, Oklahoma, United States, 73008
- Investigator
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18017
- Investigator
-
Philadelphia, Pennsylvania, United States, 19106
- Investigator
-
Philadelphia, Pennsylvania, United States, 19144
- Investigator
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Investigator
-
Nashville, Tennessee, United States, 37232
- Investigator
-
-
Texas
-
Arlington, Texas, United States, 76015
- Investigator
-
Fort Worth, Texas, United States, 76105
- Investigator
-
Fort Worth, Texas, United States, 76104
- Investigator
-
Houston, Texas, United States, 77004
- Investigator
-
Houston, Texas, United States, 77099
- Investigator
-
San Antonio, Texas, United States, 78229
- Investigator
-
-
Virginia
-
Fairfax, Virginia, United States, 22033
- Investigator
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Stage 1:
Main Inclusion Criteria:
- Adult subject ≥ 18 years of age undergoing chronic hemodialysis three or four times per week for chronic kidney disease (CKD) for at least 4 months, and expected to remain on hemodialysis three to four times weekly and be able to complete the duration of the study.
- Received IV iron therapy between 6 months and 2 weeks prior to enrollment in order to replace iron losses resulting from hemodialysis procedure.
- Mean Screening Hgb ≥ 9.5 to ≤ 11.5 grams per deciliter (g/dL).
- Mean Screening Transferrin Saturation (TSAT) ≥ 15% to ≤ 40%.
- Mean Screening serum ferritin ≥ 200 to ≤ 800 micrograms per liter (µg/L).
- If being administered epoetin, darbepoetin, or CERA, epoetin dose ≤ 45,000 Units (U)/week, darbepoetin dose ≤ 200 micrograms (µg)/week, or CERA dose ≤ 400 micrograms (µg)/month during the four weeks prior to enrollment.
Main Exclusion Criteria:
- Patient has living kidney donor identified or living-donor kidney transplant scheduled. (Note: Patients awaiting deceased-donor transplant need not be excluded.)
- Vascular access for dialysis with femoral catheter or non-tunneled catheter.
- Received a total of > 800 milligrams (mg) IV iron during the 8 weeks prior to enrollment.
- If being administered an ESA, route of administration change or ESA dose change > 35% (i.e., [max - min dose]/max dose > 0.35) over the 2 weeks prior to screening.
- Serum albumin < 3.0 grams per deciliter (g/dL) any time over the 8 weeks prior to enrollment.
- Red Blood Cell (RBC) or whole blood transfusion within 12 weeks prior to enrollment.
Stage 2:
Main Inclusion Criteria:
- Patient currently enrolled in the Stage 1 run-in period of study.
- Undergoing chronic hemodialysis three or four times per week for chronic kidney disease (CKD), and expected to remain on hemodialysis three to four times weekly and be able to complete duration of the study.
- Mean Hgb ≥ 9.5 to ≤ 11.5 g/dL over the three most recent consecutive every-week measurements prior to randomization.
- Stable Hgb defined as ≤ 1.0 g/dL difference between the maximum and minimum Hgb values over the 3 weeks immediately prior to randomization.
- Mean TSAT ≥ 15% to ≤ 40% over the two most recent consecutive every-other-week measurements prior to randomization.
- Mean serum ferritin ≥ 200 to ≤ 800 µg/L over the two most recent consecutive every-other-week measurements prior to randomization.
- If being administered epoetin, darbepoetin, or CERA, epoetin dose ≤ 45,000 U/week, darbepoetin dose ≤ 200 µg/week, or CERA dose ≤ 400 µg/month during the four weeks prior to randomization.
Main Exclusion Criteria:
- Patient has living kidney donor identified or living-donor kidney transplant scheduled. (Note: Patients awaiting deceased-donor transplant need not be excluded.)
- Vascular access for dialysis with femoral catheter or non-tunneled catheter.
- Received any amount of IV iron during the 4 weeks prior to randomization.
- If being administered an (Erythropoietin Stimulating Agent) ESA, change in dose over the 6 weeks immediately prior to randomization.
- Serum albumin < 3.0 g/dL any time over the 8 weeks prior to randomization.
- RBC or whole blood transfusion during Stage 1.
Stage 3:
Main Inclusion Criteria:
- Patient randomized in Stage 2 who has completed the full duration of Stage 2 and less than 4 weeks have elapsed since completion of Stage 2, OR
- Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for protocol-defined Protocol-Mandated Change in Anemia Management and less than 4 weeks have elapsed since withdrawal from Stage 2, OR
- Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for Hgb >11.5 g/dL over ≥ 1 week confirmed by ≥ 2 consecutive measurements AND an associated increase in Hgb by ≥ 1 g/dL over 4 weeks.
Main Exclusion Criteria:
- Patient in Stage 2 who has been prematurely withdrawn from Stage 2 for any reason other than as noted in inclusion criteria above.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Soluble Ferric Pyrophosphate (SFP) in dialysate
11 micrograms (µg) of iron / deciliter (dL) of dialysate.
|
Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
|
Placebo Comparator: Standard Dialysate
0 micrograms (µg) of iron / deciliter (dL) of dialysate.
|
Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean
Time Frame: Hgb measured weekly; up to 48 weeks from date of randomization
|
Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values.
Value is expressed as least-squares mean, along with standard error.
|
Hgb measured weekly; up to 48 weeks from date of randomization
|
Change From Baseline Hemoglobin at End-of-Treatment: Mean Baseline and End-of-Treatment Hemoglobin
Time Frame: Hgb measured weekly; up to 48 weeks from date of randomization
|
Mean change from baseline Hgb (the average of the three most recent Hgb values preceding randomization) assessments during the last one-sixth of the treatment period for patients who prematurely withdraw from study treatment, but will include a minimum of at least the last two Hgb values.
Values expressed are mean baseline and end-of-treatment Hgb, along with the mean difference (standard deviation).
|
Hgb measured weekly; up to 48 weeks from date of randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Serum Iron From Pre-Dialysis to Post-Dialysis
Time Frame: Up to 48 weeks from date of randomization
|
The mean difference between the pre-dialysis and post-dialysis serum iron was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.
|
Up to 48 weeks from date of randomization
|
Mean Change in Transferrin Saturation From Pre-Dialysis to Post-Dialysis
Time Frame: Up to 48 weeks from date of randomization
|
The mean difference between the pre-dialysis and post-dialysis TSAT (transferrin) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.
|
Up to 48 weeks from date of randomization
|
Mean Change in Unsaturated Iron-Binding Capacity (UIBC) From Pre-Dialysis to Post-Dialysis
Time Frame: Up to 48 weeks from date of randomization
|
The mean difference between the pre-dialysis and post-dialysis unsaturated iron binding capacity (UIBC) was calculated, using all post-baseline values obtained during Stage 2. Subjects could participate in Stage 2 for up to 48 weeks, provided that they did not complete Stage 2 early due to a protocol-mandated change in anemia management or withdraw from the study entirely for other reasons.
|
Up to 48 weeks from date of randomization
|
Red Blood Cell or Whole Blood Transfusion: Number of Patients Who Received a Transfusion
Time Frame: Up to 48 weeks from date of randomization
|
The number of patients requiring red blood cell or whole blood transfusion while in the randomized treatment stage (Stage 2).
Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner).
If a patient was transfused, they were withdrawn from Stage 2.
|
Up to 48 weeks from date of randomization
|
Red Blood Cell or Whole Blood Transfusion: Number of Units Transfused
Time Frame: Up to 48 weeks from date of randomization
|
The total number of units of red blood cells or whole blood that were received by patients while in the randomized treatment stage (Stage 2).
This number is the total number of units received across all randomized patients in each treatment group (it is not the average number of units received per patient).
Patients remained in Stage 2 until they met protocol-defined criteria for Stage 2 completion or until they had participated in Stage 2 for 48 weeks (whichever came sooner).
If a patient was transfused, they were withdrawn from Stage 2.
|
Up to 48 weeks from date of randomization
|
Percentage of Change From Baseline to End-of-Treatment for: Reticulocyte Hemoglobin Content (CHr), Ferritin, and the Pre-Dialysis Serum Iron Panel
Time Frame: up to 48 weeks from date of randomization
|
A comparison of the lab values at the end-of-treatment (EoT) to baseline was performed, and the percentage of change from baseline was calculated for the following lab parameters: reticulocyte hemoglobin content (CHr), Ferritin, pre-dialysis unbound iron-binding capacity (UIBC), pre-dialysis serum iron, pre-dialysis transferrin, pre-dialysis total iron-binding capacity TIBC), and transferrin saturation (TSAT).
|
up to 48 weeks from date of randomization
|
Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Pre-Dialysis Serum Iron, and Pre-Dialysis Total Iron-Binding Capacity (TIBC)
Time Frame: Up to 48 weeks from date of randomization
|
The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Unsaturated Iron-Binding Capacity (UIBC), Pre-Dialysis Serum Iron, and Pre-Dialysis Total Iron-Binding Capacity (TIBC) will be quantified.
|
Up to 48 weeks from date of randomization
|
Change From Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin (CHr)
Time Frame: Up to 48 weeks from date of randomization
|
The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Reticulocyte Hemoglobin (CHr)
|
Up to 48 weeks from date of randomization
|
Change From Baseline to End-of-Treatment (EoT) in Ferritin
Time Frame: Up to 48 weeks from date of randomization
|
The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Ferritin
|
Up to 48 weeks from date of randomization
|
Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin
Time Frame: Up to 48 weeks from date of randomization
|
The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin
|
Up to 48 weeks from date of randomization
|
Change From Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT)
Time Frame: Up to 48 weeks from date of randomization
|
The Mean Change from Stage 2 Baseline to End-of-Treatment (EoT) in Pre-Dialysis Transferrin Saturation (TSAT)
|
Up to 48 weeks from date of randomization
|
Variability of Hemoglobin Concentration: Temporal Trend
Time Frame: up to 48 weeks from date of randomization
|
The mean temporal trend of hemoglobin concentration value changes, as measured weekly from baseline until the end of participation in Stage 2.
|
up to 48 weeks from date of randomization
|
Variability of Hemoglobin Concentration: Residual Standard Deviation
Time Frame: up to 48 weeks from date of randomization
|
The mean residual standard deviation of the hemoglobin concentration changes, as measured weekly from baseline until the end of participation in Stage 2.
|
up to 48 weeks from date of randomization
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMTI-SFP-5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure Chronic Requiring Hemodialysis
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Baxter Healthcare CorporationUniversity of Louisville; Gambro Renal Products, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States
-
Kantonsspital AarauFresenius Medical Care Deutschland GmbHCompletedRenal Failure Chronic Requiring HemodialysisSwitzerland
-
Sin-Lau HospitalUnknownRenal Failure Chronic Requiring HemodialysisTaiwan
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHCompletedRenal Failure Chronic Requiring HemodialysisAustria
-
University Hospital, LimogesTerminatedRenal Failure Chronic Requiring HemodialysisFrance
-
University of PennsylvaniaTeleflex; Arrow InternationalCompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal InsufficiencyUnited States
-
Catherine SullivanCompletedRenal Failure Chronic Requiring Hemodialysis | Kidney TransplantUnited States
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States
Clinical Trials on Soluble Ferric Pyrophosphate (SFP)
-
Rockwell Medical Technologies, Inc.CompletedKidney Failure, Chronic Therapy; HemodialysisUnited States
-
Rockwell Medical Technologies, Inc.CompletedKidney FailureUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Charles Drew University of Medicine and ScienceNational Institutes of Health (NIH); Rockwell Medical Technologies, Inc.TerminatedEnd Stage Renal Disease (ESRD)United States
-
Rockwell Medical Technologies, Inc.CompletedEnd Stage Renal Disease | Chronic Kidney DiseaseUnited States, Canada
-
Rockwell Medical Technologies, Inc.CompletedEnd-Stage Renal Disease (ESRD)United States, Canada
-
Rockwell Medical Technologies, Inc.CompletedEnd Stage Renal DiseaseUnited States, Puerto Rico
-
Quadram Institute BioscienceThe Coca-Cola CompanyCompletedIron DeficiencyUnited Kingdom
-
Federal University of Juiz de ForaUnknownAnemia | Bowel Diseases, Inflammatory
-
Swiss Federal Institute of TechnologyPATHCompleted